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here is a very strong association between sleep
disturbance and major depression.The link between the
two is so fundamental that some researchers have sug-
gested that a diagnosis of depression in the absence of
sleep complaints should be made with caution.
1 Sleep dis-
turbance is one of the key symptoms of the disease,may
be the reason that depressed patients first seek help,and
is one of the few proven risk factors for suicide.
2 If sleep
problems remain after other symptoms are ameliorated,
there is a significantly increased risk of relapse and recur-
rence.Another aspect of the association is the remark-
able, if paradoxical, temporary improvement in mood
seen after total sleep deprivation in a high proportion of
depressed patients.
Incidence of sleep symptoms in depression
Symptoms of disturbed night-time sleep in people with
depression have been described extensively in both clin-
ical and epidemiological studies.In clinical samples,dif-
ficulty in initiating or maintaining sleep (including early-
morning wakening) or both have been reported in about
three quarters of all depressed patients.
3,4 In epidemio-
logical samples examining insomnia symptoms and
depression,sleep symptoms occurred in 50% to 60% in
a sample of young adults aged 21 to 30.
5 In a UK popu-
lation sample (n=8580),
6 the incidence of insomnia symp-
toms in a wide age range of patients with depression
increased with age.Overall,83% of depressed patients
had at least one insomnia symptom,compared with 36%
who did not have depression.This varied from 77% in
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Links between sleep and depression are strong. About
three quarters of depressed patients have insomnia
symptoms, and hypersomnia is present in about 40% of
young depressed adults and 10% of older patients, with
a preponderance in females. The symptoms cause huge
distress, have a major impact on quality of life, and are
a strong risk factor for suicide. As well as the subjective
experience of sleep symptoms, there are well-docu-
mented changes in objective sleep architecture in
depression. Mechanisms of sleep regulation and how
they might be disturbed in depression are discussed. The
sleep symptoms are often unresolved by treatment, and
confer a greater risk of relapse and recurrence.
Epidemiological studies have pointed out that insomnia
in nondepressed subjects is a risk factor for later devel-
opment of depression. There is therefore a need for
more successful management of sleep disturbance in
depression, in order to improve quality of life in these
patients and reduce an important factor in depressive
relapse and recurrence.  
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age group.When the authors looked at the value of sleep
symptoms as a screening aid for depression,the propor-
tion of participants with depression who reported symp-
toms of insomnia sufficient to warrant a diagnosis of
insomnia (DSM-IV) was 41%,and the proportion with-
out depression and without a diagnosis was 96%.This
supports the statement mentioned above that diagnosing
depression without sleep complaints needs care.
Hypersomnia is less common,and tends to be a feature
of atypical depression,and more prevalent in the young,
with about 40% of patients under 30 and 10% of those
in their 50s experiencing the symptom,
7 and a higher inci-
dence in females of all ages. Some patients experience
both insomnia and hypersomnia during the same depres-
sive episode.
Distress and quality of life
Disturbed sleep is a very distressing symptom which has
huge impact on quality of life in depressed patients.
8We
surveyed the views of patients with depression about their
symptoms and associated sleep difficulties.
9 In this study,
2800 members of Depression Alliance,a UK-based char-
ity for people with depression, were sent a postal ques-
tionnaire. Respondents were asked if, when they are
depressed, they suffer from sleep difficulties (Table II).
Some 97% reported sleep difficulties during depression
and 59% of these indicated that poor sleep significantly
affected their quality of life.The majority believed their
sleep difficulties started at the same time as their depres-
sion.About two thirds had sought extra treatment—such
as prescribed sleeping pills,over-the-counter sleeping aids,
and extra visits to their doctor—for their sleep problems.
In another recent study,
10 depressed patients reported
significantly poorer perceptions of sleep quality and
poorer perceptions of life quality and mood than the
control group, even though estimates of sleep distur-
bance were similar. This may indicate that depressed
individuals experience more “sleep distress” than
healthy individuals.
Physiological findings in depression
As well as the distressing symptoms of sleep disturbance
experienced by patients,changes in objective sleep archi-
tecture are well-documented in depression.
11 Compared
with normal controls,sleep continuity of depressed sub-
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Selected abbreviations and acronyms
5-HT serotonin
REM rapid eye movement
SSRI selective serotonin reuptake inhibitor
SWA slow-wave actvity
SWS slow-wave sleep
• Insomnia is common in depression  • Sleep architecture is 
and may be the presenting complaint abnormal in depression
• Sleep disturbance may predict  • Antidepressants change
treatment outcome, including relapse sleep architecture in
and recurrence  the opposite direction
• Sleep manipulation alters mood
Table I. Sleep and depression are strongly linked.
Nature of sleep and daytime symptoms %
Sleep disturbance symptoms (n=496) 
Any 97
i) I can’t get off to sleep 58
ii) I keep waking up in the night 59
iii) I wake early and can’t get back to sleep 61
iv) I sleep for too long 31
Insomnia only (i, ii and/or iii) 69
Hypersomnia only (iv) 10
Mixed insomnia/hypersomnia 21
Associated daytime symptoms (n=491) 99
I can’t concentrate 81
I feel exhausted and lethargic 80
I have no energy 77
I feel very sleepy 41
I nap during the day 40
Extra treatment sought (n=341) 69
Prescribed sleeping pills 48
Over-the-counter sleeping aids 29
Extra visits to the doctor 24
Effect on QOL (n=495)
Not at all 2
A little 10
Moderately 29
A lot 35
Very much 24
Onset of sleep problems (n=483)
A long time before my depression 16
About the same time as my depression 68
Table II. Sleep disturbance symptoms: nature, onset, effect on quality of
life (QOL), and further treatment sought.
9jects is often impaired,with increased wakefulness (more
frequent and longer periods of wakefulness), and
reduced sleep efficiency. Sleep onset latency is signifi-
cantly increased and total sleep time reduced.Rapid eye
movement (REM) latency is often shortened, and the
duration of the first REM period is increased (Figure 1).
The number of eye movements in REM (REM density)
is also increased.
Slow-wave activity (SWA) seen on the electroen-
cephalogram (EEG) during non-REM sleep is a marker
of the homeostatic drive to sleep; thus, the amount of
SWA is greatest in the first sleep cycle when sleep
propensity is high, and gradually diminishes in subse-
quent cycles as sleep debt is made up and sleep drive
diminished.The total amount of SWS is often decreased
in depression, compared with normal controls.
11 This
reduction may be related to decreased regional cerebral
blood flow seen in the orbitofrontal and anterior cingu-
late cortex during slow-wave sleep (SWS) in imaging
studies,
12 and it may be a consequence of the abnormal-
ities in this area described in depression.
13 In addition,
reduction in SWS can reflect fragmented sleep in gen-
eral,such as is seen in depression.
Another anomaly seen in depressed patients is that the
normal pattern of SWA decreasing from the first to the
last NREM episode is disrupted,with less of a decrease
in SWA occurring from the first to the second episode in
depressed patients
14,15 (Figure 2). This is sometimes
expressed as a lower delta sleep ratio (DSR) that is the
quotient of SWA in the first to the second non-REM
period of sleep.
Some of these sleep architecture abnormalities are present
during full clinical remission,and also appear to be asso-
ciated with an increased risk for relapse.
16-18 High REM
density and reduced SWS in the first cycle were also pre-
sent in first-degree relatives of depressed patients in the
Munich Vulnerability Study on Affective Disorders,mea-
sured on two occasions 4 years apart,
19 and in a more
recent study,REM density predicted those who had sub-
sequently developed a major depressive episode.
20
Mechanisms of sleep regulation 
and disturbances in depression
Research over the past 25 years has revealed that the
sleep-wake cycle is regulated by two separate but inter-
acting processes,
21 the circadian (C) process and the
homeostatic (S),or recovery process.
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Figure 1. Hypnograms from a normal subject (upper) and a depressed
patient (lower). The depressed patient has a shortened REM
sleep latency, very little slow-wave (stages 3 and 4) sleep, par-
ticularly in the first sleep cycle, more awakening, and a long
period of waking at about 0430. 
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Figure 2. Evolution of slow-wave activity over the night in a normal sub-
ject (upper) and a depressed patient (lower). In the normal sub-
ject the amount of slow-wave activity is high in the first non-
REM period, then diminishes over the night. In the depressed
patient, the highest activity is in the second non-REM period.
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0 0 60 120 180 240 300 360 420 480The C process is that which regulates the daily rhythms
of the body and brain.Circadian (24-h) patterns of activ-
ity are found in many organs and cells,and the main cir-
cadian pacemaker is found in a group of cells in the
suprachiasmatic nucleus (SCN) of the hypothalamus.
These cells provide an oscillatory pattern of activity
which drives rhythms such as sleep-wake activity, hor-
mone release,liver function,etc.This drive from the SCN
is innate,self-sustaining,and independent of tiredness or
amount of sleep.It is affected markedly by light and to
some extent by temperature.Bright light in the evening
will delay the clock, and bright light in the morning is
necessary to synchronize the clock to a 24-hour rhythm;
in constant light or darkness the cycle length is about 24.3
h.All animals have such a clock,and the period and tim-
ing appear to be dependent on particular genes,which
are similar in fruit flies and mammals.
The drive to sleep from the circadian clock in normal
sleepers starts to increase slowly at about 11 PM and grad-
ually reaches a peak at about 4 AM.This provides a sleep-
promoting process which continues into mid-morning
and then provides a wakefulness-promoting process dur-
ing the day.The timing of REM sleep is linked to the cir-
cadian rhythm,closely mirroring the core temperature.
Thus,the maximum propensity for REM sleep is usually
after the nadir of core temperature,around 6 AM,and it
is less likely to occur during an afternoon and evening
nap.
21
The homeostatic or recovery drive to sleep (the S
process) is wake-dependent,ie,it increases in proportion
to the amount of time since last sleep.Its usual maximum
is at about 11 PM,or about 16 hours after waking up in
the morning,and then decreases during sleep,with a min-
imum at natural waking in the morning.When sleep has
been shorter than usual there is a “sleep debt” which
leads to an increase in the S process—this works to
ensure that the debt is made up at the next sleep period,
by accelerating the time to sleep and possibly by increas-
ing sleep depth and duration.
These two processes interact to promote the onset of
sleep when both are high (at the usual bedtime), and
maintain sleep when the C process is high and the S
process is declining (in the early hours of the morning).
SWA (see above) is a marker of the homeostatic drive to
sleep; thus, the amount of SWA is greatest in the first
sleep cycle when sleep propensity is high,and gradually
diminishes in subsequent cycles as sleep debt is made up
and sleep drive diminished.
Sleep abnormalities in depression,both subjective and
objective,point to a disruption in both homeostatic and
circadian drives to sleep.A frequently occurring symp-
tom is taking a long time to initiate sleep,
3 which is com-
mon to some other psychiatric conditions, particularly
generalized anxiety disorder.
23 It may be that general
hyperarousal, or psychic anxiety, which is present in
about 80% of depressed patients,may be a contributory
factor in this early insomnia.The alteration in timing or
evolution of SWA may be thought of as a disruption in
the normal S process,resulting in a decreased pressure to
sleep.This hypothesis has never been tested properly in
depressed patients, although its validity may be sup-
ported by the effects of sleep deprivation (see below).In
addition,effective treatment with antidepressant drugs
tends to restore the profile of SWA towards normal,
23 but
it is difficult to disentangle these effects on SWA from
those on REM sleep.
14
In contrast,alterations in REM latency,increase in wak-
ing and stage 1 sleep, and waking early point to the C
process being affected;in depression patients would have
an earlier onset of key sleep rhythms.Whether the circa-
dian rhythm disruption is a cause, a consequence, or a
comorbid condition of depression is the subject of much
research at present,as the underlying genetic control of
the mammalian clock is becoming clearer,and investiga-
tion of clock genes in depression more common.Some
interesting data has emerged linking some of these genes
with sleep in bipolar disorder
25 and with the response of
insomnia in depression to treatment with antidepres-
sants
26;however,there is little as yet which clarifies the
relationship between circadian genes and sleep in unipo-
lar depression.Another theory relates to deficiencies in
key neurotransmitters such as serotonin (5-HT),nora-
drenaline,or acetylcholine leading to phase advance of
sleep rhythms in depression.
Evidence for both S and C processes being implicated in
depression is contained in the phenomenon of total sleep
deprivation improving mood the next day in major depres-
sion,which has been known and used for many years.
27This
is an extension of the well-known feature seen in many
patients with severe depression that mood is worse in the
mornings and gradually improves during the day, to the
point that it can be in the normal range just before bed—
only to revert back to depression during sleep.However,
keeping patients awake all night is difficult to perform,and
once they are allowed uninterrupted sleep all the benefi-
cial effects of sleep deprivation disappear.Recent research
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332has refined the methods of manipulation of sleep and cir-
cadian rhythm to maximize its effects on mood by bringing
the sleep period forward,
27 and there have been several
strategies proposed to prolong the therapeutic effect such
as adding drug interventions and strictly controlling the
amount and type of sleep allowed in the following days.
28,29
It can be argued that this intervention works to increase the
pressure for sleep (homeostatic process) and on basic cir-
cadian function in the brain,supporting a “phase advance”
of circadian rhythm in depression which is corrected by
sleep manipulation.Further evidence is gained from stud-
ies showing that those patients who respond to sleep depri-
vation and to light treatment are those in whom phase
advance has been demonstrated by actimetry (a technique
which measures sleep-wake cycles using movement sensors
worn for many weeks on the wrist).
30
There is evidence from animal studies of an immediate
increase in 5-HT,noradrenaline,and dopamine function
in rat brain after sleep deprivation.
31 Neuroimaging stud-
ies provide some evidence that in depressed patients,the
metabolic hyperactivity seen in the anterior cingulate in
depression is corrected by sleep deprivation.
32,33Thus the
effects of sleep deprivation may be mediated via multi-
ple brain systems.
Sleep in depressed patients may be more sensitive to life
events which disrupt daily rhythms.Haynes et al
34 rated
these events in a group of depressed patients and mea-
sured sleep disruption by actigraphy.Depressed patients
who had experienced social rhythm-disrupting events,for
instance overseas travel,being fired from a full-time job
without immediately starting another,starting full-time
college,or marital separation,had much more wakeful-
ness during the night compared with those patients with-
out these events,and this difference was not evident in
normal controls.
Increased risk of depression in insomnia
The National Institute of Mental Health Epidemiologic
Catchment Area study 20 years ago interviewed 7954
adults on two occasions a year apart,and this study first
highlighted the strong association between sleep distur-
bance and subsequent depression.They found that 14%
of those who had insomnia at the first interview had
developed new major depression a year later.
35This data
has been augmented by several more recent reports of
increased risk.Breslau et al,
5 in a survey of 1200 young
adults in Michigan, found that the odds ratio of new
depression in was 4 times increased in those subjects who
had insomnia 3 years earlier,and in a questionnaire sur-
vey of adults over 18 in the UK there was a 3-fold
increased risk of new depression if subjects had reported
one sleep problem occurring “on most nights”a year ear-
lier.
36 Doctors in a prospective study who had complained
of insomnia during medical school in the 1950s and 1960s
were twice as likely to have developed depression at fol-
low-up in 1990s.
37
It is apparent that sleep problems often appear before
other depression symptoms,
38 and that subjective sleep
quality worsens before onset of an episode in recurrent
depression.
39
Residual insomnia: relapse and recurrence
There is much evidence that effective antidepressant treat-
ments can successfully elicit significant response in depres-
sion, but is much less evidence that effective treatment
fully addresses the problem of sleep disturbance.Persistent
insomnia is one of the most common residual symptoms
in patients with incomplete remission.
40 This presents a
problem, given the fact that residual insomnia confers
greater risk of subsequent depression:in a study of “remit-
ted”patients maintained on a selective serotonin reuptake
inhibotor (SSRI) and psychotherapy,
41 subjective sleep
problems and anxiety were each found to be predictors of
early recurrence.The origin of these residual symptoms of
insomnia is probably multifactorial, reflecting ongoing
functional brain abnormalities as well as adverse effects of
some drug treatments,for example SSRIs,particularly flu-
oxetine,can lead to insomnia.
Implications for treatment
Anomalies in sleep architecture in depression are linked
with treatment outcome;for instance they may predict
poor response to cognitive behavioral therapy (CBT)
42
and interpersonal therapy,
43 and more patients experi-
ence a recurrence of depression after successful CBT
treatment if they have an abnormal sleep profile.
42
Response to antidepressant drug treatment is not pre-
dicted by sleep EEG abnormalities; however, placebo
nonresponse is more likely in those patients with an
abnormal sleep profile.
44
Selective serotonergic drugs are the present first-line ther-
apy for depression, and there is much evidence for the
involvement of 5-HT in the pathogenesis of both depres-
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depletion,which reduces brain 5-HT function,results in a
temporary return of depressive symptoms in recovered
depressed patients,
45 and a reduction in REM latency.
46
SSRIs which increase 5-HT function increase REM
latency, and reduce REM sleep.
47 However, although
SSRIs, serotonin-norepinephrine reuptake inhibitors
(SNRIs),and venlafaxine are effective and widely used,
they may worsen sleep disturbance early in treatment
48,49
and may leave residual sleep symptoms once mood is
improved.
50 Benzodiazepine and Z-drug hypnotics (non-
benzodiazepine hypnotics, such as zolpidem and zopi-
clone) are often required to deal with these adverse
effects,which can lead to problems with dependence and
withdrawal.However,in a study in which eszopiclone was
added to fluoxetine in depressed patients
51 there were sig-
nificant beneficial effects,even in depressive symptoms
other than insomnia items.
Some antidepressants can have a beneficial effect on
sleep.These include mianserin,trazodone,nefazodone,
and mirtazapine,as well as the older tricyclic antidepres-
sants.The mechanisms underlying this are complex and
relate to interactions (blockade) of certain neurotrans-
mitter receptors—with significant 5-HT antagonist prop-
erties being a common theme—though antagonism at
histamine H1 and noradrenaline α1 receptors also plays
a part for some of these drugs.
In conclusion
Subjective and objective sleep disturbance in depression
is prevalent,distressing,and often unresolved by treat-
ment.It indicates significant alterations in brain neuro-
transmitter function, as well as leading to significant
impairments in quality of life and further treatment-seek-
ing by sufferers,so increasing the burden on health care
services.There is therefore a need for more successful
management of sleep disturbance in depression,in order
to improve quality of life in these patients and reduce an
important factor in depressive relapse and recurrence. ❏
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Los trastornos del sueño como síntomas
nucleares de la depresión
El sueño y la depresión están fuertemente relacio-
nados. Cerca de tres cuartas partes de los pacientes
depresivos tienen síntomas de insomnio, y la hiper-
somnia se presenta en alrededor del 40% de los
adultos jóvenes con depresión y en el 10% de los
pacientes de mayor edad, con un predominio entre
las mujeres. Los síntomas provocan un inmenso dis-
trés, tienen un gran impacto en la calidad de vida y
constituyen un potente factor de riesgo para el sui-
cidio. Además de la experiencia subjetiva de los sín-
tomas del sueño, en la depresión existen cambios
bien documentados en la arquitectura objetiva del
sueño. En este artículo se discuten los mecanismos
de la regulación del sueño y cómo ellos pueden
estar alterados en la depresión. Los síntomas del
sueño a menudo no se resuelven con el trata-
miento, y aportan un mayor riesgo de recaídas y
recurrencias. Los estudios epidemiológicos han
señalado que el insomnio en los sujetos sin depre-
sión es un factor de riesgo para que más adelante
se desarrolle este cuadro. Por lo tanto, se requiere
de un manejo más exitoso de los trastornos del
sueño en la depresión para mejorar la calidad de
vida de estos pacientes y para reducir un factor
importante en las recaídas y recurrencias depresi-
vas.  
Les troubles du sommeil, symptôme majeur
de dépression
Le sommeil et la dépression sont fortement liés.
Environ trois quarts des patients déprimés souffrent
d’insomnie et l’hypersomnie existe chez à peu près
40 % des jeunes adultes déprimés et 10 % des
patients plus âgés avec une prédominance fémi-
nine. Ces symptômes sont responsables d’une
grande souffrance, ils diminuent beaucoup la qua-
lité de vie et sont un facteur de risque important de
suicide. Les modifications de l’architecture objective
du sommeil dans la dépression sont aussi bien docu-
mentées que les troubles subjectifs du sommeil. Les
mécanismes de régulation du sommeil et la
manière dont ils peuvent être perturbés lors de la
dépression sont discutés. Les troubles du sommeil
persistent souvent en dépit du traitement, et repré-
sentent un grand risque de récidive et de rechute.
Des études épidémiologiques ont souligné que l’in-
somnie chez des sujets non déprimés est un facteur
de risque de dépression ultérieure. Il est donc néces-
saire que les troubles du sommeil soient mieux pris
en charge dans la dépression afin d’améliorer la
qualité de vie chez ces patients et de réduire ce fac-
teur important de récidive et  de rechute dépres-
sive. 
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